Navigation Links
Angiotech announces positive results from Bio-Seal(TM) clinical study
Date:3/9/2009

or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and ot
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 ... the "Global Lactic Acid  (Biodegradable Polymer, Food ... Trends & Forecasts to 2019" report to ... simplest hydroxyl-carboxylic acid with an asymmetrical carbon atom. ... the biodegradable polymer, food and beverage, personal care ...
(Date:8/27/2014)... -- Reportbuyer.com has added a new market research ... Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... similar amount of hype currently surrounds graphene, with ... water treatment, but is graphene the only solution? ... Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... Aug. 27, 2014 Tris Pharma, a specialty ... today announced that it has been selected as an ... Association,s 2014 Awards for Excellence competition in ... independent panel of judges from SCORE (Counselors to America,s ... will be honored at a gala event to be ...
(Date:8/27/2014)... College, PA (PRWEB) August 27, 2014 ... Simulation Software with new features for the biomedical ... is an enhanced Biological Thermal Sensor, exclusive to the ... a specialty version of XFdtd, developed to calculate the ... export functionality has been added to all versions to ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... DIEGO, Aug. 15, 2011 NexBio announced top line ... an investigational drug for treatment and prophylaxis of Influenza-Like ... influenza and parainfluenza viruses, including pandemic influenza strains. In ... adults infected with influenza virus, treatment with DAS181 resulted ...
... of NMR/MRI technology with a unique version of ... the U.S. Department of Energy (DOE),s Lawrence Berkeley ... to a portable system for highly sensitive multi-dimensional ... impossible with conventional technologies. Alexander Pines, a ...
... threat to humans, as emphasized by the recent effects of ... July 21st by the Cell Press journal Developmental Cell ... and divergent strategies that different toxins use to invade a ... derived from the castor bean plant that has raised concerns ...
Cached Biology Technology:NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography 2Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography 3Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography 4Targeting toxin trafficking 2
(Date:8/27/2014)... we want to listen carefully to someone, the first ... we do is stop moving altogether. This strategy helps ... our own movements. , This interplay between movement and ... Indeed, indirect evidence has long suggested that the brain,s ... cortex, which gives rise to our conscious perception of ...
(Date:8/27/2014)... depicted as giant, frightening beasts. But every creature is ... rock slab containing fossils of 24 very young dinosaurs ... of hatchlings overseen by a caretaker, according to a ... Brandon P. Hedrick and Peter Dodson led the work, ... History, where the specimen is held. Hedrick is a ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... drug developers, finding an agent that kills tumor cells is ... healthy cells, and ideally its effects will be ... University of Illinois researchers report that they have assembled a ... all of the above. The findings appear this month in ...
... plants are at their peak bloom and climbing plants, like ... only are these plants beautiful, but their ability to climb ... that has taken millions of years to accomplish. A ... in the July issue of the American Journal of ...
... of fossil fuels has released tremendous amounts of the greenhouse gas ... climate. Were it not for the absorption of CO 2 ... concentration would be substantially greater than it is. However, this ... does not come without undesired consequences. When dissolved, CO 2 ...
Cached Biology News:New cancer drug delivery system is effective and reversible 2New cancer drug delivery system is effective and reversible 3Climbing to new heights in the forest canopy 2University of Hawaii at Manoa researchers reveal ocean acidification at Station ALOHA 2
Incomplete Adjuvant...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
Biology Products: